FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to embodiments of IgG-Fc polypeptides of domestic animals. Invention provides obtaining polypeptide IgG-Fc components having low binding affinity with C1q and CD16 and/or low antibody-dependent cell cytotoxicity (ADCC), as well as fused polypeptides based thereon with GLP-1 or glucagon, having increased half-life in blood serum.
EFFECT: invention can be used in veterinary science for treating diabetes, obesity and metabolic disease associated with diabetes or obesity.
61 cl, 7 dwg, 10 tbl, 17 ex
| Title | Year | Author | Number |
|---|---|---|---|
| VERSIONS OF Fc-REGION WITH ALTERED BINDING TO NEONATAL Fc-RECEPTOR (FcRn) FOR USE IN VETERINARY SCIENCE | 2019 |
|
RU2830231C2 |
| NGF ANTAGONISTS FOR MEDICAL USE | 2020 |
|
RU2829812C2 |
| PARVOVIRUS ANTIBODIES FOR USE IN VETERINARY SCIENCE | 2020 |
|
RU2830441C2 |
| IL4/IL13 RECEPTOR MOLECULE FOR VETERINARY USE | 2018 |
|
RU2795591C2 |
| CD47-ANTIGEN-BINDING UNIT AND ITS USE | 2018 |
|
RU2780859C2 |
| ANTI-IL31 ANTIBODIES FOR VETERINARY USE | 2018 |
|
RU2795485C2 |
| IL-10/FC FUSION PROTEINS SUITABLE AS IMMUNOTHERAPY ENHANCERS | 2020 |
|
RU2825306C1 |
| ANTIBODY AGAINST CLAUDIN 18A2 AND ITS USE | 2020 |
|
RU2811431C2 |
| NEW ANTIBODY COMPOSITIONS FOR CANCER IMMUNOTHERAPY | 2019 |
|
RU2804490C2 |
| HUMAN COAGULATION FACTOR FUSED PROTEIN FX (FIX), METHOD FOR PRODUCTION AND USE THEREOF | 2017 |
|
RU2736339C1 |
